Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Recurrence × TQ-B3525 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 1 Sarcoma, Ewing 1 Recurrence 1 Ovarian Neoplasms 1 Osteosarcoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma 1 HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1 Chondrosarcoma 1

Interventions

Cyclophosphamide 16 fludarabine 12 Dexamethasone 12 Cisplatin 11 Rituximab 10 Gemcitabine 8 Lenalidomide 7 Cytarabine 7 Bendamustine Hydrochloride 7 fludarabine phosphate 6 Paclitaxel 6 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6 Decitabine 6 Bortezomib 6 Radiotherapy 5 Injections 5 Etoposide 5 Carboplatin 5 camrelizumab 4 apatinib 4 Valproic Acid 4 Thalidomide 4 Procarbazine 4 Oxaliplatin 4 Antilymphocyte Serum 4 tislelizumab 3 pomalidomide 3 Vinorelbine 3 Vinblastine 3 Radiosurgery 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03510767 2023-04-14

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Unknown

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡